Cantor Fitzgerald, Goldman Sachs and Zacks also have a “buy” rating on the stock, according to the report.
AmSurg has a 52-week low of $44.61 and 52-week high of $70.53.
More articles on transactions and valuation issues:
Surgery Center South in Alabama files CON for expansion
New ASC opening at Rockaway Beach: 8 things to know
SurgCenter Development, physicians to open $2M JV surgery center in Ohio: 3 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
